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The topic of the study is important. When considering (semi-)annual CT lung cancer screening, radiation dose is a significant factor. Image quality needs to be sufficient to accurately detect and quantify lung nodules, and as low as reasonably achievable to limit accumulating dose in apparently healthy screenees.
There are already quite a number of studies that compare the detectability and size measurements of ultra-low-dose CT and lowdose CT in patient /nodule groups with similar numbers. Most have been performed in Asian populations, with on average somewhat lower patient size. There have also been a couple of studies in Western populations. The studies are adequately referenced. Patients with high BMI are excluded in the current study. It seems the truly real aspect of the current study is the use of a newer iterative reconstruction protocol.
It is unclear why the authors have selected 90% sensitivity for nodules with at least 4 mm diameter as the outcome for power analysis. For screening purposes, it is important not to miss any potentially relevant nodules, so is 10% acceptable? It seems the power analysis is now aimed at proving this 10% difference. Would it not be better to show equality in detectability? In addition, from analyses in incidence screening rounds in the Nelson study, it is known that new nodules with a size of 30 mm3 (about 3 mm) are already important to note (Walter, Lancet Oncology 2016).
1. Is there any pilot research data/images examples that can indicate the image quality status? 2. Please describle in detail about qualtative/quantative assesment about image quality such as image noisy/ nosiy index (GE revolution vendor) or scoring system by reviewers 3. Previous study addressed that patient Size-Specific Analysis of Dose Indexes From CT Lung Cancer Screening. The CTDIvol is constant at 0.24mGy in this protocol. Are there any pilot studies to illustrate image quality and actual image examples? In addition, patient-size based CTDIvol may be more approriate for this ULD study design. Reference: AJR Am J Roentgenol. 2017 Jan;208(1):144-149. doi: 10.2214/AJR.16.16082. Epub 2016 Oct 11. 4. Nodule classification may be affected as a result according to Fleschier guideline or novel classfication system such as (pure GGN/heterogenous GGN or part-solid nodule. To investigate the interobsever/intraobserver variability based on these classfication system, the study result will be more robust. References: 1. Semiquantative visual assessment of sub-solid pulmonary nodules≦ 3 cm in differentiation of lung adenocarcinoma spectrum; Scientific reports 7 (1), 15790 1) The study protocol concerns a comparison of low-dose CT (as used in CT lung cancer screening) to an ultra-low-dose CT protocol in 150 patients. Primary outcome is the detectability of lung nodules with a diameter of 4 mm or more. The study seems to have (nearly) finished as last scanning was expected to take place in September 2018.
Indeed, the last patient was included October 23/2018 but the data collection work is not completed: the blind reading of nodules parameters is still in progress and it will be followed by consensus for cases with discordance between the two radiologists. We estimate to need about 3 months to finish the data collection.
2) The topic of the study is important. When considering (semi-)annual CT lung cancer screening, radiation dose is a significant factor. Image quality needs to be sufficient to accurately detect and quantify lung nodules, and as low as reasonably achievable to limit accumulating dose in apparently healthy screenees.
There are already quite a number of studies that compare the detectability and size measurements of ultra-low-dose CT and low-dose CT in patient /nodule groups with similar numbers. Most have been performed in Asian populations, with on average somewhat lower patient size. There have also been a couple of studies in Western populations. The studies are adequately referenced. Patients with high BMI are excluded in the current study. It seems that the innovative aspect of the current study is the use of a new iterative reconstruction protocol. This is true. We used a new iterative reconstruction by GEMS, ASIR-V at different percentage for ultralow dose CT (ULD CT) as compare to low dose CT. our goal is to demonstrate that ULD CT is as sensitive as LD CT for detecting nodules with a possible use in screening programs.
3) It is unclear why the authors have selected 90% sensitivity for nodules with at least 4 mm diameter as the outcome for power analysis. For screening purposes, it is important not to miss any potentially relevant nodules, so is 10% acceptable? It seems the power analysis is now aimed at proving this 10% difference. Would it not be better to show equality in detectability?
We agree that high sensitivity is important for screening purpose. Nevertheless, in this study involving a new iterative reconstruction protocol, the methodology of the study has been thought in such a way to be first convinced of the relevance of this new approach in the respect of feasibility in a realistic time and in a single center. That's why we selected 90%, this threshold being also based on clinical results of previous ULD CT studies (Sui X, Meinel FG, Song W, Xu X, Wang Z, Wang Y, et al. Detection and size measurements of pulmonary nodules in ultra-low-dose CT with iterative reconstruction compared to low dose CT. Eur J Radiol. Mars 2016;85(3):564-70) and enabling the feasibility of this study in our center. Two scenarios are possible at the end of the study: either the result is statistically significant, and the choice of this threshold will be discussed as well as the question of the relevance of performing a new study with an optimized sensitivity threshold (taking into account the new reconstruction method); or the result is not statistically significant, with a need to rethink the appropriateness of this approach. Furthermore, as far as we know, our study is the only one among previous ULD CT studies to perform statistical sample size calculation.
In addition, from analyses in incidence screening rounds in the Nelson study, it is known that new nodules with a size of 30 mm3 (about 3 mm) are already important to note (Walter, Lancet Oncology 2016). Thus, it is important to set a lower diameter limit for desired detectability. (12):e754-66); the size for prevalent nodule to be considerate as indeterminate is 5mm < nodule < 10 mm at baseline ; the size for incidental nodule to be considerate as indeterminate at follow up CT is 4 to < 8mm. Therefore, our choice seems in agreement with these thresholds.
With this in mind, the current study may be underpowered. Please consider repeating the power analysis and including the additional number of patients. Also, it is unclear if the power is sufficient for the many secondary analyses.
In a clinical study, the calculation of the sample size is done only for the primary objective. So indeed, it may be possible that the power is not sufficient for secondary outcomes (we do not know), but it is usually that way for all clinical studies, the secondary objectives being indeed purely exploratory. 4) According to the British Thoracic Society and the European position statement on lung cancer screening, volumetry of lung nodules should be performed instead of diameter measurements. (Semiautomated) volumetry is more accurate than (manual) diameter measurement, and allows for sensitive growth detection. It would be important that the authors analyze their data using volumetry as size measurement.
We agree that volumetry is more is suitable as it is more reproducible. We plan to perform such study as secondary analysis and we will compare 2 software (from Philips and GEMS).
5) Specific comments:
Would it not be better to reconstruct isotropic voxels (slice thickness 1mm or less)? Indeed NELSON study is using a slice thickness of 1 mm with an increment of 0.7mm, but for NLST study, slice thickness was from 1 to 3.2mm, and for other ULD CT study, this was more than 1mm: for example 2mm for Messerli and al. In our protocol we increased size thickness from 0.625 to 1.25mm (GE Revolution CT scanner) in order to lower radiation dose and noise. Besides, our reconstruction scan interval is 1mm, so we believe this is sufficient for lung screening purpose.
Can the radiation dose be 6.65 mSv in a low dose CT acquisition protocol in patients with BMI <35?
No this is very unlikely.
6.65msv is the referent dose level given by French radiation protection institute. This condition was added in a rare case of a protocol mistake by the technician, in order not to deliver more than this limit. In our institution we conducted a pilot study with the local engineer to set up parameters for ULD CT.
We assessed the noise on both 3 sets of images. We also decided to perform ULDCT with the lowest dose possible with our CT machine. This is an example of a subsolid nodule:
2) Please describle in detail about qualtative/quantative assesment about image quality such as image noisy/ nosiy index (GE revolution vendor) or scoring system by reviewers For each acquisition, we evaluate -noise by measuring the standard deviation in a region of interest placed in the tracheal air just above the carina (surface of ROI is also recorded).
Subjective quality on a 3-point scale: excellent image quality, good image quality (diagnostic), non-diagnostic quality -Shape of trachea which indicates inspiration or expiration.
For every patient, we check for control quality, ie, the use of the proposed CT procotol, pitch value, slice thickness, kVp and if all reconstructions were performed. In our institution we conducted a pilot study with local engineer to set up parameters for ULD CT : we first tested mA modulation with a high noise index (80), but CTDIvol was kept constant with Revolution CT, even if patient was obese. As we have deliberately chosen to use the lowest dose possible dose with this machine, we have decided to keep mAs and kVp constant for the ULD acquisition.
we have also calculated and report SSDE for every patient.
4) Nodule classification may be affected as a result according to Fleschner guideline or novel classfication system such as (pure GGN/heterogenous GGN or part-solid nodule. To investigate the interobsever/intraobserver variability based on these classfication system, the study result will be more robust.
This is the case, interobsever and intraobserver are secondary objectives and will be calculated for all nodule criteria, emphysema, coronary calcification and bronchial modification.
References:
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GENERAL COMMENTS
The authors have answered most of the questions satisfactorily. Main concerns remain regarding the test used for power analysis. The power analysis test seems now aimed at proving 10% difference between low dose CT and ultra low dose CT. The hypothesis needs to be rejected if there is (statistically) less than 10% difference -however this does not show equivalence of the scans. The hypothesis for power analysis does seem the opposite of what the authors are trying to prove: namely that there is no relevant difference between LDCT and ULDCT. For that purpose, equivalence or non-inferiority testing is needed. See f.e. Vonder, J Cardiovascular Compute Tomogr 2018. Please discuss this issue with a statistician.
In addition, in view of the recommendations of the EU Position statement and others, the advice is to use volumetry as the primary evaluation method -not the secondary, as the authors aim for application in screening. As the authors are in scan evaluation phase, it seems possible to include volumetry directly in the primary analyses?
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GENERAL COMMENTS
This paper presented a protocol to compare ultra-low 2 dose chest CT and standard low-dose CT. The proposed method could be beneficial in clinical practice. However, some concerns and comments are as following:
1) In study design, "…. We chose to only include nodules ≥ 4mm as the incidence of cancer is very low below this threshold, and are not currently considered as clinically significant", this may result in overestimate of sensitivity.
2) "The normality of the quantitative parameters will be determined by the Shapiro-Wilks test or by graphical verification of the symmetry of the distribution. When the normality of the distribution of such a parameter has been demonstrated, it will be described by its mean and its standard deviation". Are you going to check the normality of those continuous independent variables? Why?
3) In "If the missing data rate of the primary criterion is between 5% and 20%, the missing data for this criterion will be replaced", what does it mean "the primary criterion"? Do you mean the CT scan is missing? Or something else?
4) "In order to maintain an overall threshold of 5% in the final analysis, the interim analysis will be carried out with a threshold of 0.1%", what does it mean threshold here? What is the stopping criterion used and how to justify the criterion can maintain the overall threshold of 5% in the final analysis? The LDCT group corresponds to the reference group, there will always in this group a detection rate of nodules of 100%. For this reason, we didn't want to make a comparison of the detection rate of nodules between the two groups with an equivalence or non-inferiority test. Instead, we have chosen to do a study in which we would like to obtain a sensibility of nodules detection of 90%.
VERSION 2 -AUTHOR RESPONSE
2) In addition, in view of the recommendations of the EU Position statement and others, the advice is to use volumetry as the primary evaluation method -not the secondary, as the authors aim for application in screening. As the authors are in scan evaluation phase, it seems possible to include volumetry directly in the primary analyses?
We agree that the volumetry will be the standard technique for managing lung nodules. Unfortunately, our study has been conceived before the recommendations of the EU Position statement published at the end of 2017. Therefore, volumetry will be a secondary objective of this study and we are in the process of testing the influence of ULDCT acquisitions with different % of iterative reconstruction as compared to LDCT for the detection of pulmonary nodules.
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The proposed method could be beneficial in clinical practice. However, some concerns and comments are as following:
1)
In study design, "…. We chose to only include nodules ≥ 4mm as the incidence of cancer is very low below this threshold, and are not currently considered as clinically significant", this may result in overestimate of sensitivity.
We agree that the sensitivity of detection may be higher. However, nodules < 3mm are considered as micronodules (Bankier A et al. Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society Radiology 2017;285:584-600). Therefore, Bankier et al recommend that nodules 3 mm or smaller should not be measured, given inherent accuracy limitations and variability in determining whether the lesion is a solid, part-solid, or ground-glass nodule.
To follow good statistical practices: the normality of all quantitative parameters will be determined by the Shapiro-Wilks test or by graphical verification of the symmetry of the distribution. When the normality of the distribution of such a parameter has been demonstrated, it will be described by its mean and its standard deviation. Otherwise it will be described by its median, the 25th and the 75th percentile.
3)
In "If the missing data rate of the primary criterion is between 5% and 20%, the missing data for this criterion will be replaced", what does it mean "the primary criterion"? Do you mean the CT scan is missing? Or something else?
The primary criterion is the presence / absence of nodules on the scanners. In case of difficulty to read the scanners, they are reviewed by several radiologists in confrontation session. There will be no missing data for the main criterion. The sentence is removed from the article.
4)
"In order to maintain an overall threshold of 5% in the final analysis, the interim analysis will be carried out with a threshold of 0.1%", what does it mean threshold here? What is the stopping criterion used and how to justify the criterion can maintain the overall threshold of 5% in the final analysis?
We used the method of Peto and Haybittle: the intermediate comparisons are carried out with a very low threshold (0.1%), which consumes little alpha risk and makes it possible to take a threshold of 5% for the final analysis. With this method, a study can be stopped prematurely only if a very highly significant result is obtained during an intermediate analysis.
